Such approaches targeting VEGF-C/VEGF-D/VEGFR-3 have the potential to block the lymphogenous spread of cancer as well as tumor growth and hematogenous spread given this signaling axis can contribute to tumor angiogenesis [11, 14]. The gene discussed is VEGFD; the disease is cancer.